|
|
||||||||||||||
|
|
|||||||||||||||
REPORT |
| Assessment: domains and instruments |
1 Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, USA
2 Department of Dermatology, University of Utah Health Sciences Center, Salt Lake City, UT, USA
Correspondence to:
Correspondence to:
Dr S R Feldman
Wake Forest University School of Medicine, Department of Dermatology, Medical Center Boulevard, Winston-Salem, NC 27157-1071, USA; sfeldman{at}wfubmc.edu
In clinical practice, broad global assessments of psoriasis disease activity and its effect on patients quality of life are used to assess the severity of patients disease and their response to treatment. In clinical trials, more objective, validated instruments are required. Several such instruments have been developed and continue to be developed to provide an assessment of the severity of the skin lesions. Because a lesions impact on patients lives varies widely among patients, there has been growing recognition of the need to measure the quality of life impact of the disease along with the severity of the lesions.
Abbreviations: DLQI, Dermatology Life Quality Index; NPF-PS, National Psoriasis Foundation Psoriasis Score; PASI, Psoriasis Area and Severity Index; PGA, physician global assessment
Keywords: PASI; measurement; skin disease; quality of life
This article has been cited by other articles:
![]() |
T. Nijsten, C. W. N. Looman, and R. S. Stern Clinical Severity of Psoriasis in Last 20 Years of PUVA Study Arch Dermatol, September 1, 2007; 143(9): 1113 - 1121. [Abstract] [Full Text] [PDF] |
||||
![]() |
P J Mease, C E Antoni, D D Gladman, and W J Taylor Psoriatic arthritis assessment tools in clinical trials Ann Rheum Dis, March 1, 2005; 64(suppl_2): ii49 - ii54. [Abstract] [Full Text] [PDF] |
||||
![]() |
P J Mease, F Behrens, W-H Boehncke, S R Feldman, O FitzGerald, D D Gladman, P S Helliwell, P Nash, I Olivieri, W J Taylor, et al. Discussion: Assessment of psoriatic arthritis Ann Rheum Dis, March 1, 2005; 64(suppl_2): ii69 - ii73. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |